Clinical Trials Browser

Breast Carcinoma In Situ, Breast Neoplasms, Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Oropharyngeal Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Inflammatory Breast Neoplasms

NCT00898326 2017-06-02

SHIP36B

Completed

198 enrolled

Genitourinary

Prostatic Neoplasms

NCT03174054 2017-06-02

The Value of PSMA-PET Compared With Multi-parametric MRI in the Detection Prostate Lesions

Unknown

70 enrolled

Genitourinary

Prostatic Neoplasms

NCT00373035 2017-01-19

Biomarkers in Patients Undergoing Transrectal Ultrasound Prostate Biopsy

Completed

60 enrolled

Genitourinary

Prostatic Neoplasms

NCT00459407 2014-10-08

Defined Green Tea Catechins in Treating Patients With Prostate Cancer Undergoing Surgery to Remove the Prostate

Phase 1 Completed

50 enrolled

Genitourinary

Prostatic Neoplasms

NCT00416390 2013-09-20

Lycopene in Treating Patients With Prostate Cancer or Benign Prostatic Hyperplasia

Phase NA Completed

120 enrolled

Genitourinary

Neoplasms, Prostatic Hyperplasia, Prostatic Neoplasms

NCT00561314 2013-08-26

High-Intensity Focused Ultrasound Ablation in Treating Patients With Localized Prostate Cancer

Phase 2 Completed

33 enrolled

GenitourinaryOther

Prostatic Neoplasms, Sexual Dysfunction, Physiological, Urinary Incontinence

Clinical Trials

Mechanisms of Resistance to PSMA Radioligand Therapy

Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer

Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer

Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

Evaluation of Treatment Response Using Multiparametric MRI After Prostate Radiotherapy

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

MOSAIC

Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer

Feasibility of OmnEcoil System for Integrated Endorectal MRI and Transrectal MRI-Targeted Biopsy of the Prostate

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate Cancer

PRAISE-U

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

PROFILE

Imaging of Solid Tumors Using 18F-TRX

Tumor Microenvironment Analysis of Prostate Cancer Metastasis

Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer

IP6-CHAIROS

CheckPRO

PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer

Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

SMMART Adaptive Clinical Treatment (ACT) Trial

MR-PROPER

Observation or Radical Treatment in Patients With Prostate Cancer

PERFECT

ProstaPilot

PRIMUS

PROMPT

GENCADE

Polyunsaturated Fatty Acids in Treating Patients With Prostate Cancer Undergoing Prostate Biopsy and/or Surgery

Omega-3 Fatty Acids in Treating Patients With Advanced Prostate Cancer

Magnetic Resonance Imaging to Locate and Characterize Prostate Cancer

EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma

SHIP36B

The Value of PSMA-PET Compared With Multi-parametric MRI in the Detection Prostate Lesions

Biomarkers in Patients Undergoing Transrectal Ultrasound Prostate Biopsy

Defined Green Tea Catechins in Treating Patients With Prostate Cancer Undergoing Surgery to Remove the Prostate

Lycopene in Treating Patients With Prostate Cancer or Benign Prostatic Hyperplasia

High-Intensity Focused Ultrasound Ablation in Treating Patients With Localized Prostate Cancer